ACET — Adicet Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1720580 ·
Last close
$5.74
Market Cap
$53.73M
52W High
$17.44
52W Low
$5.55
ADV30
268,264
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -22,301,000 | -21,358,000 | 148,166,000 | 33,131,000 | 28,028,000 |
| Mar 2026 | 0 | — | -21,570,000 | -20,244,000 | 169,382,000 | 36,245,000 | 29,317,000 |
| Dec 2025 | 0 | — | -31,886,000 | -30,516,000 | 192,355,000 | 38,918,000 | 33,145,000 |
| Sep 2025 | 0 | — | -27,952,000 | -26,856,000 | 140,479,000 | 29,099,000 | 31,337,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-84,529,000
Investing CF
$7,831,000
Financing CF
$75,075,000
CapEx
$-495,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-11.45
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-656,299,000
Inventory
—
Receivables
$439,000
ST Investments
$85,059,000
EBIT TTM
$-98,750,000
Pretax Income TTM
$-98,831,000
Interest Exp TTM
$81,000
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,114,000 | -116,803,000 | 192,355,000 | 33,145,000 | 159,210,000 | -95,246,000 |
| Dec 2024 | 0 | -127,615,000 | -117,122,000 | 220,219,000 | 33,610,000 | 186,609,000 | -92,378,000 |
| Dec 2023 | 0 | -132,576,000 | -142,658,000 | 207,295,000 | 37,120,000 | 170,175,000 | -93,717,000 |
| Dec 2022 | 24,990,000 | -72,551,000 | -69,790,000 | 330,690,000 | 38,352,000 | 292,338,000 | -44,765,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-108,833,000
OpCashFlow TTM
—
Assets (Latest)
$169,382,000
Forward EPS
$-4.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZYBT | Zhengye Biotechnology Holding Ltd | $54.50M | $1.15 | — |
| CNTB | Connect Biopharma Holdings Ltd | $55.46M | $0.88 | — |
| ATHE | ALTERITY THERAPEUTICS LTD | $55.90M | $3.07 | — |
| TLPH | TALPHERA, INC. | $56.06M | $1.08 | — |
| SER | Serina Therapeutics, Inc. | $51.05M | $2.01 | — |
News headlines (Yahoo Finance, 1h cache)
Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
2026-10-03 01:02 · Yahoo
Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance
2026-09-28 14:54 · Yahoo
Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients
2026-09-28 12:13 · Yahoo
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
2026-09-25 20:00 · Yahoo
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
2026-09-03 13:55 · Yahoo
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
2026-09-03 13:40 · Yahoo
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 20:00 · Yahoo
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2026-08-31 21:39 · Yahoo
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
2026-08-27 20:00 · Yahoo
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
2026-08-18 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.